NCT06137599 (GCS) is a clinical trial of Capillary analysis in CHEMICAL SUBMISSION, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT06137599?

NCT06137599 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT06137599?

Interventions in NCT06137599: Capillary analysis.

What condition does NCT06137599 study?

NCT06137599 studies CHEMICAL SUBMISSION.

Is NCT06137599 still recruiting?

NCT06137599 is currently recruiting now. Last updated 3 July 2024.

Last reviewed 2024-07-03 · How we verify

NCT06137599: GCS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GCS Survey: "GHB IN CHEMICAL SUBMISSION: MYTH OR REALITY?"

Recruiting now Last updated 3 July 2024

What this trial tests

trial testing Capillary analysis in CHEMICAL SUBMISSION in 200 participants. Currently enrolling.

Timeline

20 March 2024

Primary endpoint
20 March 2025

20 March 2026

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	20 March 2024
Primary completion	20 March 2025
Estimated completion	20 March 2026
Sites	3 locations across France

Drugs / interventions tested

Capillary analysis

Conditions studied

CHEMICAL SUBMISSION — all drugs for CHEMICAL SUBMISSION →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with CHEMICAL SUBMISSION. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

According to the media, GHB is the main substance used for chemical submission. The national survey conducted by the Addictovigilance centre of Paris on drug-facilitated assaults shows that GHB is used, but only in a very small proportion of cases. However, the short detection times for this substance point to its possible under-detection (06-09h in blood, 10-12h in urine). A pilot research protocol in Ile de France focusing on capillary analysis is therefore being proposed to volunteer victims to overcome this bias and answer this question: is the massive use of GHB in chemical submission a myth or a reality?

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06137599 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 3 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06137599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing